BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:26 pm Purchase |
2024-09-30 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 8,089,795 9.990% |
1,386,906 (+20.69%) |
Filing |
| 2024-02-14 10:09 am Purchase |
2023-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 6,702,889 9.990% |
107,088 (+1.62%) |
Filing |
| 2022-07-29 4:37 pm Purchase |
2022-07-27 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 6,595,801 10.100% |
792,101 (+13.65%) |
Filing |
| 2022-01-03 4:34 pm Purchase |
2021-12-21 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,803,700 8.900% |
2,884,229 (+98.79%) |
Filing |
| 2021-05-03 5:19 pm Sale |
2021-04-29 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 2,919,471 4.500% |
-2,657,000 (-47.65%) |
Filing |
| 2021-02-11 5:27 pm Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% |
950,060 (+20.54%) |
Filing |
| 2020-11-10 4:58 pm Purchase |
2020-11-06 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 4,626,411 10.000% |
1,437,463 (+45.08%) |
Filing |